EDIT - CIK 0001650664
Editas Medicine, Inc. trades as EDIT. In its fiscal 2025 annual report the company posted revenue of $40.52M, up 25.4% from the prior year and net income of -$160.06M. This page tracks Editas Medicine, Inc. through 693 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Editas Medicine, Inc.'s revenue grew from $6.05M to $40.52M, a compound annual growth rate of 23.5%. Net profit margin expanded from -1605.5% to -395.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Prospectus supplement | 424B5 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| S-3MEF | - | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
The largest companies sharing Editas Medicine, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Editas Medicine, Inc. reported revenue of $40.52M for fiscal year 2025, an increase of 25.4% year over year.
In its latest fiscal year Editas Medicine, Inc. reported a net loss of $160.06M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.